Stockreport

DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years

DBV Technologies S.A. - American Depositary Shares  (DBVT) 
US:NASDAQ Investor Relations: dbv-technologies.com/en/investor-relations
PDF Châtillon, France, November 11, 2025 DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allerg [Read more]